Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Measuring Macrophage Activation Markers and Influence on Bile Acid Composition in Patients With Primary Biliary Cholangitis After Treatment With Bezafibrate
University of Aarhus
100 participants
Oct 1, 2020
OBSERVATIONAL
Conditions
Summary
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.
Eligibility
Inclusion Criteria1
- PBC patient offered bezafibrate treatment
Exclusion Criteria5
- patient age under 18
- life expectancy less than 6 months
- known cancer
- planned liver transplantation within 6 months
- other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood sampling
Measurement of liver stiffness
Question about pruritus
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04514965